These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37884415)

  • 1. Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adults.
    Tricou V; Winkle PJ; Tharenos LM; Rauscher M; Escudero I; Hoffman E; LeFevre I; Borkowski A; Wallace D
    Vaccine; 2023 Nov; 41(47):6999-7006. PubMed ID: 37884415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
    Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated dengue vaccine in adults.
    Gunale B; Farinola N; Yeolekar L; Shrivastava S; Girgis H; Poonawalla CS; Dhere RM; Arankalle V; Chandra Mishra A; Mehla R; Kulkarni PS
    Vaccine; 2023 Aug; 41(38):5614-5621. PubMed ID: 37532611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: A phase 2, double-blind, randomised, controlled trial.
    Tricou V; Low JG; Oh HM; Leo YS; Kalimuddin S; Wijaya L; Pang J; Ling LM; Lee TH; Brose M; Hutagalung Y; Rauscher M; Borkowski A; Wallace D
    Vaccine; 2020 Feb; 38(6):1513-1519. PubMed ID: 31843269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country.
    Tricou V; Eyre S; Ramjee M; Collini P; Mojares Z; Loeliger E; Mandaric S; Rauscher M; Brose M; Lefevre I; Folschweiller N; Wallace D
    Vaccine; 2023 Feb; 41(7):1398-1407. PubMed ID: 36681529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial.
    Turner M; Papadimitriou A; Winkle P; Segall N; Levin M; Doust M; Johnson C; Lucksinger G; Fierro C; Pickrell P; Raanan M; Tricou V; Borkowski A; Wallace D
    Hum Vaccin Immunother; 2020 Oct; 16(10):2456-2464. PubMed ID: 32119591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Children and Adults: A Randomized, Placebo-Controlled, Phase 2 Study.
    Sirivichayakul C; Barranco-Santana EA; Rivera IE; Kilbury J; Raanan M; Borkowski A; Papadimitriou A; Wallace D
    J Infect Dis; 2022 May; 225(9):1513-1520. PubMed ID: 32658250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial.
    Tricou V; Sáez-Llorens X; Yu D; Rivera L; Jimeno J; Villarreal AC; Dato E; Saldaña de Suman O; Montenegro N; DeAntonio R; Mazara S; Vargas M; Mendoza D; Rauscher M; Brose M; Lefevre I; Tuboi S; Borkowski A; Wallace D
    Lancet; 2020 May; 395(10234):1434-1443. PubMed ID: 32197107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Jimeno J; Villarreal AC; Dato E; Mazara S; Vargas M; Brose M; Rauscher M; Tuboi S; Borkowski A; Wallace D
    Lancet Infect Dis; 2018 Feb; 18(2):162-170. PubMed ID: 29122463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study.
    Torresi J; Heron LG; Qiao M; Marjason J; Chambonneau L; Bouckenooghe A; Boaz M; van der Vliet D; Wallace D; Hutagalung Y; Nissen MD; Richmond PC
    Vaccine; 2015 Sep; 33(39):5127-34. PubMed ID: 26279339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated Vaccine Candidate.
    Patel SS; Rauscher M; Kudela M; Pang H
    Clin Infect Dis; 2023 Feb; 76(3):e1350-e1359. PubMed ID: 35639602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study.
    Hss AS; Koh MT; Tan KK; Chan LG; Zhou L; Bouckenooghe A; Crevat D; Hutagalung Y
    Vaccine; 2013 Dec; 31(49):5814-21. PubMed ID: 24135573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial.
    Tricou V; Yu D; Reynales H; Biswal S; Saez-Llorens X; Sirivichayakul C; Lopez P; Borja-Tabora C; Bravo L; Kosalaraksa P; Vargas LM; Alera MT; Rivera L; Watanaveeradej V; Dietze R; Fernando L; Wickramasinghe VP; Moreira ED; Fernando AD; Gunasekera D; Luz K; Oliveira AL; Tuboi S; Escudero I; Hutagalung Y; Lloyd E; Rauscher M; Zent O; Folschweiller N; LeFevre I; Espinoza F; Wallace D
    Lancet Glob Health; 2024 Feb; 12(2):e257-e270. PubMed ID: 38245116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
    Coronel-MartÍnez DL; Park J; López-Medina E; Capeding MR; Cadena Bonfanti AA; Montalbán MC; Ramírez I; Gonzales MLA; DiazGranados CA; Zambrano B; Dayan G; Savarino S; Chen Z; Wang H; Sun S; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
    Lancet Infect Dis; 2021 Apr; 21(4):517-528. PubMed ID: 33212067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18-49 years of age: Results of a randomized phase 3 study.
    Baker J; Aliabadi N; Munjal I; Jiang Q; Feng Y; Brock LG; Cooper D; Anderson AS; Swanson KA; Gruber WC; Gurtman A
    Vaccine; 2024 May; 42(13):3172-3179. PubMed ID: 38616438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.
    Biswal S; Borja-Tabora C; Martinez Vargas L; Velásquez H; Theresa Alera M; Sierra V; Johana Rodriguez-Arenales E; Yu D; Wickramasinghe VP; Duarte Moreira E; Fernando AD; Gunasekera D; Kosalaraksa P; Espinoza F; López-Medina E; Bravo L; Tuboi S; Hutagalung Y; Garbes P; Escudero I; Rauscher M; Bizjajeva S; LeFevre I; Borkowski A; Saez-Llorens X; Wallace D;
    Lancet; 2020 May; 395(10234):1423-1433. PubMed ID: 32197105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City.
    Biswal S; Mendez Galvan JF; Macias Parra M; Galan-Herrera JF; Carrascal Rodriguez MB; Rodriguez Bueno EP; Brose M; Rauscher M; LeFevre I; Wallace D; Borkowski A
    Rev Panam Salud Publica; 2021; 45():e67. PubMed ID: 34131423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in healthy adults: an observer-blind, randomised, phase 1 trial.
    Han HH; Diaz C; Acosta CJ; Liu M; Borkowski A
    Lancet Infect Dis; 2021 Sep; 21(9):1282-1292. PubMed ID: 34019802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study.
    Tricou V; Essink B; Ervin JE; Turner M; Escudero I; Rauscher M; Brose M; Lefevre I; Borkowski A; Wallace D
    PLoS Negl Trop Dis; 2023 Mar; 17(3):e0011124. PubMed ID: 36888687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial.
    Dubey AP; Agarkhedkar S; Chhatwal J; Narayan A; Ganguly S; Wartel TA; Bouckenooghe A; Menezes J
    Hum Vaccin Immunother; 2016; 12(2):512-8. PubMed ID: 26291554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.